Neumora Therapeutics, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMRA research report →
Companywww.neumoratx.com
Neumora Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
- CEO
- Daljit Singh Aurora
- IPO
- 2023
- Employees
- 110
- HQ
- Watertown, DE, US
Price Chart
Valuation
- Market Cap
- $325.17M
- P/E
- -1.42
- P/S
- 0.00
- P/B
- 4.47
- EV/EBITDA
- -0.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -181.70%
- ROIC
- -179.83%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-236,928,000 · 2.81%
- EPS
- $-1.45 · 5.23%
- Op Income
- $-241,156,000
- FCF YoY
- -12.85%
Performance & Tape
- 52W High
- $3.65
- 52W Low
- $0.66
- 50D MA
- $2.27
- 200D MA
- $2.19
- Beta
- 3.05
- Avg Volume
- 1.21M
Get TickerSpark's AI analysis on NMRA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 17, 26 | Aurora Daljit Singh | sell | 6,165 |
| Feb 17, 26 | Pinto Joshua | sell | 5,967 |
| Feb 17, 26 | BERNS PAUL L | sell | 9,819 |
| Feb 17, 26 | Milligan Michael Lee | sell | 1,436 |
| Jan 8, 26 | Milligan Michael Lee | other | 350,000 |
| Jan 8, 26 | Aurora Daljit Singh | other | 750,000 |
| Jan 8, 26 | Duncan Jason | other | 750,000 |
| Jan 8, 26 | Pinto Joshua | other | 1,200,000 |
| Jan 8, 26 | BERNS PAUL L | other | 1,650,000 |
| Nov 11, 25 | Aurora Daljit Singh | sell | 114,703 |
Our NMRA Coverage
We haven't published any research on NMRA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NMRA Report →